SOPHiA GENETICS SA announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM? Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.

Chronic Lymphocytic Leukemia (CLL) is a complex and critical condition, that accounts for 25?30 percent of all the leukemia in Western Countries, with over 100,000 incidence cases and over 40,000 death cases globally reported in 2019. With the implementation of SOPHiA GENETICS' technology, Laboratorio Barnafi-Krause is the exclusive laboratory in Chile equipped to conduct next-generation sequencing (NGS) for CLL. This new capability, made possible by SOPHiA GENETICS and its advanced, AI-powered solution, underscores the collaborative initiatives aimed at refining diagnostic approaches and treatment strategies for leukemia patients in Chile.

With the SOPHiA DDM? Platform, Laboratorio Barnafi-Krause will offer tailored NGS-based workflows that enable accurate and sensitive characterization of the complex mutational landscape associated with blood disorders. SOPHiA DDM?

provides high-quality, reproducible data and streamlined insights on up-to-date gene panels in a matter of days, helping to expedite and advance research and support clinicians in making data-driven recommendations for patients. Through the use of the SOPHiA DDM? Platform, Laboratorio Barnafi-Krause will move forward in its work to reshape the landscape of genomic medicine in Chile and improve outcomes for patients in the battle against leukemia.